5 results
The main objective of the trial is to identify at least one NGR that will demonstrate all of the following:1. Inhibition of ovulation2. Cycle control that is non-inferior to NuvaRing®, as judged by the incidence ofBTB-S during Treatment Cycle 3. The…
The aim of the present study is to assess the contraceptive potential of the association of UPA 30 mg single dose and desogestrel 75 micrograms for 20 days. The study will also assess the potential possible interaction, (in terms of ovarian activity…
Primary Objective: The primary objective of this study is to evaluate safety and tolerability of pridopidine in patients with HD.Secondary Objectives: The secondary objectives of the study are to assess the effects of long-term, open-label dosing…
The primary objective of the study is:- To evaluate the pharmacodynamics effects on follicular growth and ovulation of one dose of 30 mg UPA taken before dominant follicle selectionThe secondary objectives are:- To determine the pharmacokinetics…
The primary objective of this study is to assess the efficacy of pridopidine 67.5 to 112.5 mg twice daily (bid) on motor impairment in patients with HD after 26 weeks of treatment using the Unified Huntington*s Disease Rating Scale (UHDRS) Total…